Acceder

Farmas USA

136K respuestas
Farmas USA
86 suscriptores
Farmas USA
Página
6.642 / 17.034
#53131

Re: Farmas USA

 

Synta Reports Third Quarter Financial Results and Provides Corporate Update

http://phx.corporate-ir.net/phoenix.zhtml?c=147988&p=irol-newsArticle&ID=1986592

Research and development expenses were $16.2 million for the third quarter in 2014, compared to $17.6 million for the same period in 2013. General and administrative expenses were $3.2 million for the third quarter in 2014, compared to $4.2 million for the same period in 2013.

The Company reported a net loss of $20.0 million, or $0.19 per basic and diluted share, in the third quarter of 2014, compared to a net loss of$22.5 million, or $0.33 per basic and diluted share, for the same period in 2013.

As of September 30, 2014, the Company had $119.3 million in cash, cash equivalents and marketable securities, compared to $91.5 million in cash, cash equivalents and marketable securities as of December 31, 2013.

 

In the third quarter of 2014, the Company raised an aggregate of approximately $28.1 million in net proceeds from the sale of its common stock under its at-the-market (ATM) issuance sales agreements with MLV & Co.

Leñe!! una dilucion ATM en Q3??? Y nosotros sin enterarnos!!!!!

 

119,3 millones en cash y 20 kilos de quemado en este ultimo trimestre. Pues me temo que habra otra dilucion en 2015 aunque la empresa diga que no esperan mas. Llegar a fin de año 2015 con apenas 40 kilos en cash ... a eso yo lo llamo quedarse muy justico de pasta. Diluiran de nuevo. 

SNTA

 

#53132

Re: Farmas USA

7Soles
M.Gracias
MSTX
Excecelent analysis and information
Y mas en estos dias que no puedo hacerlo yo

#53133

Re: Farmas USA

SNTA

Synta Pharma (NASDAQ: SNTA) reported Q3 EPS of ($0.19), $0.05 better than the analyst estimate of ($0.24).
Based on its current operating levels, the Company expects its cash resources of approximately $119.3 million at September 30, 2014 will be sufficient to fund operations at least into the fourth quarter of 2015.

Efectivamente, diluirán pronto. Lo decía yo para los trimestrales de agosto:

Hicieron dilución en diciembre de 2012 y noviembre de 2013.
No habrá fase 3 hasta finales 2015, con lo que puede gotear y seguir goteando mucho más tiempo.
En junio de 2013 dijeron "we expect our cash resources as of June 30, 2013 will be sufficient to fund operations into the second quarter of 2014" y se cascaron dilución en noviembre de 2013.

En agosto de 2014 dijeron "will be sufficient to fund operations at least into the fourth quarter of 2015"

Sin mirar sus cuentas ni nada espero dilución entre octubre y junio, aunque hasta febrero aún no lo veo demasiado peligroso.

«Después de nada, o después de todo/ supe que todo no era más que nada.»

#53134

Re: Farmas USA

SNTA

Primera noticia que tengo. Los muy sinvergüenzas se las arreglan para ocultar las ATM. Cuando hacen una se publica como marca la ley pero luego las noticias desaparecen de los lugares más buscados. Mira en FINVIZ que no sale una noticia antigua anunciando ATM's ni en SNTA ni en MSTX

#53136

Re: Farmas USA

No se si he encontrado algo relevante, creo que si:

 Cadila Pharmaceuticals Ltd.  , con quien esta asociada NVAX en joint venture en la India usando la tecnologia NVAx.
 
Rabies G Protein Vaccine study for immunization against Rabies
 

http://www.ctri.nic.in/Clinicaltrials/pdf_generate.php?trialid=8347&EncHid=&modid=&compid=%27,%278347det%27

OTRO ESTUDIO QUE VA BIEN. LUEGO LO REVISO CON MAS CALMA.

Cadila Pharmaceuticals Limited, India has successfully tested VLP-based Rabies G Protein Vaccine in
preclinical models and to take the development further, it needs to be tested in humans. Present study is the
FIH trial involving Rabies G Protein Vaccine to evaluate its safety and immunogenicity. When new rabies
vaccines are introduced, their immunogenicity is evaluated by comparing the RABV neutralizing antibody
titres induced by the vaccine being tested with those induced by a vaccine of demonstrated efficacy. As rabies
is a fatal disease, randomized controlled human trials involving untreated comparison groups could not be
carried out for ethical reasons.8 Lesser doses (2 or 3) of post-exposure prophylaxis might see savings to
healthcare system and individuals in terms vaccine cost and additional medical visits, in addition to overall
better treatment compliance. Based on our preclinical experience and above statements, we postulate that
Rabies G Protein Vaccine will provide faster and similar seroprotection against rabies in comparison to
worldwide approved Rabipur vaccine as a simulated post-exposure immunization in healthy volunteers.
 
 
NVAX